Our mission is to inspire and drive the breaking ground research in cardiovascular clinical practice taking the lead in translational and clinical studies, managing expert-level cardiovascular imaging service, contributing to the development of the novel imaging tools (professional artificial intelligence and machine learning-based cardiovascular imaging software), medical devices, promising biomedical engineering and nanotechnology solutions, national and international professional standards of health care in general and interventional cardiology, cardiovascular imaging, disseminating the knowledge to the scientific professional community and the general public, supporting the highest standards of quality and safety in both imaging and therapy in order to pave the way toward the dramatic reduction of cardiovascular burden across the globe rescuing millions of lives.

DHRF pioneers and develops the advanced cardiovascular service and imaging, innovative medical devices which are based on artificial intelligence, biomedical engineering, and nanomedicine nourishing research and progress


Founder, C.E.O., and Independent Researcher


  • E3AF8286-04D8-4C98-90C7-E5BEDAE08490
  • LinkedIn
  • Twitter

De Haar Research Task Force (DHRF, DHRF Pro)

Tallinn, Estonia | Rotterdam - Amsterdam, The Netherlands

Fostering High-Quality Fair Research and Scientific Perfectionism

Advanced Cardiovascular Imaging in Non-Invasive and Interventional Cardiology

Bioresorbable Scaffolds with Sensors and Nanoparticles (Electronic Stent)

Artificial Womb and Transhumanism

(Gender-Free Future)

Public Health in Cardiology and Artificial Intelligence

Consciousness and Theory of Everything, Philosophy of Science

The idea of DHRF (aka De Haar Research Foundation) was born in Rotterdam on February 15th, 2013. Task Force develops and supports innovations in interventional cardiology, medical device development (including electronic bioresorbable scaffolds), intracoronary/ intravascular (QCA, IVUS, OCT, NIRS, photoacoustics) and non-invasive imaging (MSCT/ CCTA, CMR, MPI, PET, TTE), including artificial intelligence/ machine learning-based technologies, biomedical engineering (including the artificial womb), neurophysiology (mostly, consciousness), and nanomedicine (multifunctional nanoparticles for theranostics of atherosclerosis). The DHRF provides start-ups and small enterprises in the Netherlands, Estonia, the United States, and countries of the Commonwealth of Nations with the relevant research service and assistance representing, promoting, and supporting their biomedical business in Europe as well as the relevant translational and clinical studies including CE mark procedures. The DHRF currently is an SME-business located in Tallinn (Estonia) and Rotterdam - Amsterdam (the Netherlands) with ambitions of the further development and expansion inside the Lowlands, Europe and in the United States.

Thus, De Haar Research Task Force provides the service as follows:

  • development of the advanced (artificial intelligence/ machine learning-based) cardiovascular imaging software; 

  • independent expert imaging CoreLab analysis of invasive cardiovascular imaging approaches such as QCA, OCT, IVUS (with the professional validated software) as well as non-invasive imaging particularly CCTA, CMR;

  • consultancy and research assistance in cardiovascular nanomedicine (translational studies, RTD);

  • RTD of the technologies related to the artificial womb, AI-based imaging software, multifunctional bioresorbable scaffolds with incorporated nanomedical technologies;

  • medical device consultancy in interventional cardiovascular biomedicine (vascular biology, biomedical engineering, coronary devices, interventional cardiology, translational studies);

  • research assistance in the development of the artificial womb;

  • clinical trial management in Russia (no E.U. or U.S. requirements are needed) and Europe - special support for the U.S., E.U., Asian preclinical or clinical trial sponsors/ enterprises (including start-ups with the proof-of-concept studies) with the European academic scientific back-up;

  • scientific assistance of applications for CE mark and FDA in interventional cardiovascular and nanomedical topics;

  • medical concierge service, and medical tourism in the European Union and the Netherlands;

  • scientific assistance of the independent (external) imaging software validation;

  • Grant writing for European Commission and the Dutch governmental projects;

  • scientific article writing;

  • medical device and software proctoring service.